<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624881</url>
  </required_header>
  <id_info>
    <org_study_id>BWI_2017_06</org_study_id>
    <nct_id>NCT03624881</nct_id>
  </id_info>
  <brief_title>Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)</brief_title>
  <official_title>Evaluation of the VISITAG SURPOINT™ Module With External Processing Unit (EPU) When Used With the THERMOCOOL SMARTTOUCH® SF and the THERMOCOOL SMARTTOUCH® Catheters for Pulmonary Vein Isolation (PVI) (SURPOINT COA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosense Webster, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, non-randomized, post market clinical evaluation of the VISITAG SURPOINT™ Module&#xD;
      with External Processing Unit (EPU) when used with STSF catheter and ST catheter compared to&#xD;
      an historical control performance goal.&#xD;
&#xD;
      A maximum of 330 subjects will be enrolled across up to 45 sites. Two hundred eighty (280)&#xD;
      enrolled subjects will be treated using the STSF catheter with EPU and 50 subjects will be&#xD;
      treated using the ST catheter with EPU. Prior to enrollment, a few sites will be selected to&#xD;
      only enroll subjects who will be treated with the ST catheter and the remaining sites will&#xD;
      only enroll subjects who will be treated with the STSF catheter.&#xD;
&#xD;
      Bayesian adaptive design will be used to assess early success at up to two interims: one&#xD;
      after all subjects have completed the 3- month follow-up assessment, and a second to occur&#xD;
      after all subjects have completed the 6 months follow-up visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, non-randomized, post market clinical evaluation of the VISITAG SURPOINT™ Module&#xD;
      with External Processing Unit (EPU) when used with STSF catheter and ST catheter compared to&#xD;
      an historical control performance goal.&#xD;
&#xD;
      A maximum of 330 subjects will be enrolled across up to 45 sites. Two hundred eighty (280)&#xD;
      enrolled subjects will be treated using the STSF catheter with EPU and 50 subjects will be&#xD;
      treated using the ST catheter with EPU. Prior to enrollment, a few sites will be selected to&#xD;
      only enroll subjects who will be treated with the ST catheter and the remaining sites will&#xD;
      only enroll subjects who will be treated with the STSF catheter.&#xD;
&#xD;
      Bayesian adaptive design will be used to assess early success at up to two interims: one&#xD;
      after all subjects have completed the 3- month follow-up assessment, and a second to occur&#xD;
      after all subjects have completed the 6 months follow-up visit.&#xD;
&#xD;
      The primary objective of this clinical investigation is to demonstrate the safety and&#xD;
      12-month effectiveness of Tag Index-guided ablation using the VISITAG SURPOINT™ Module with&#xD;
      External Processing Unit when used with the THERMOCOOL SMARTTOUCH® SF (STSF) and THERMOCOOL&#xD;
      SMARTTOUCH® (ST) catheters for pulmonary vein isolation (PVI) in the treatment of subjects&#xD;
      with drug refractory symptomatic paroxysmal atrial fibrillation. Specifically:&#xD;
&#xD;
        -  To demonstrate the safety based on the proportion of subjects with early-onset (within 7&#xD;
           days of ablation procedure) primary adverse events&#xD;
&#xD;
        -  To demonstrate the 12-month effectiveness based on the proportion of subject with&#xD;
           freedom from documented atrial arrhythmia (atrial fibrillation (AF), atrial tachycardia&#xD;
           (AT) or atrial flutter (AFL) episodes during the effectiveness evaluation period (Day&#xD;
           91-365)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 4, 2018</start_date>
  <completion_date type="Actual">June 28, 2021</completion_date>
  <primary_completion_date type="Actual">June 28, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Safety- Incidence of early onset primary adverse events (PAE)</measure>
    <time_frame>12 months</time_frame>
    <description>The primary safety endpoint is the incidence of any primary adverse event occurring within 7 days following an AF ablation procedure (including the initial and repeat procedures) using the STSF/ST catheter with the EPU per protocol, except atrio-esophageal fistula and PV stenosis, which may also be considered as primary adverse events if occurring greater than seven (7) days post the ablation procedure.&#xD;
Primary adverse events include the following conditions:&#xD;
Death&#xD;
Atrio-esophageal fistula&#xD;
Cardiac Tamponade*+/Perforation+&#xD;
Myocardial infarction (MI)&#xD;
Stroke / Cerebrovascular accident (CVA) †, ††&#xD;
Thromboembolism&#xD;
Transient Ischemic Attack&#xD;
Diaphragmatic paralysis&#xD;
Pneumothorax&#xD;
Heart block&#xD;
PV stenosis&#xD;
Pulmonary edema (Respiratory Insuffciency)&#xD;
Vagal Nerve Injury&#xD;
Pericarditis&#xD;
Major vascular access complication / bleeding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12 month effectiveness- Freedom from documented (Symptomatic and asymptomatic) atrial tachyarrhythmias&quot;</measure>
    <time_frame>12 month</time_frame>
    <description>Freedom from documented (Symptomatic and asymptomatic) atrial fibrillation, atrial flutter and atrial tachycardia (AF/AFL/AT) (hereinafter collectively referred to as &quot;atrial tachyarrhythmias&quot;) recurrence (episodes ≥ 30 secs on TTM or continuously recorded on the standard 12-leads ECG or 24 Hour Holter monitoring) during the evaluation period (Day 91-365)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety- Cumulative incidence of primary adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>o 12-Month PAE Rate: Cumulative incidence of primary adverse events occurring within seven (7) days following an AF ablation procedure using study catheters with EPU and any late onset atrio-esophageal fistula or PV stenosis through 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary safety-Incidence of Unanticipated Adverse Device Effects (UADEs)</measure>
    <time_frame>12 months</time_frame>
    <description>o Incidence of Unanticipated Adverse Device Effects (UADEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety- Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>12 Months</time_frame>
    <description>o Incidence of Serious Adverse Events (SAEs) within 7 days (early onset), &gt;7 to 30 days (peri-procedural) and &gt;30 days (late onset) of initial ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety- Incidence of bleeding complication</measure>
    <time_frame>12 Months</time_frame>
    <description>o Incidence of bleeding complication: a) major bleeding, b) clinically relevant non-major, and c) minor bleeding as defined in the 2017 HRS/EHRA/ECAS/APHRS /SOLAECE Consensus Statement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary effectiveness: Acute procedural Success</measure>
    <time_frame>12 months</time_frame>
    <description>Acute Procedural success:&#xD;
% of subjects with ipsilateral PVI (entrance block) at the end of the procedure&#xD;
% of subjects with ipsilateral PVI (entrance block) after first encirclement (evaluated prior to the 30-minute waiting period and adenosine challenge)&#xD;
% of subjects with ipsilateral PVI (entrance block) after first encirclement without acute reconnection, after waiting period and adenosine challenge&#xD;
% of touch-up (ablation of acute reconnection) among all targeted veins&#xD;
Anatomical location of acute PV reconnection after first encirclement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary- Effectiveness: Repeat ablation procedures post-procedure</measure>
    <time_frame>12 Months</time_frame>
    <description>Repeat Ablation Procedures:&#xD;
Incidence (%) of repeat ablation procedures with VISITAG SURPOINT™ module during 12-months period post-procedure&#xD;
% PVs re-isolated among all of the targeted PVs at repeat procedure&#xD;
% repeat ablation procedures requiring new linear lesions and/or identifying new foci outside of initially isolated area among the repeat ablation procedures</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">333</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>VISITAG SURPOINT Module with EPU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Catheter ablation with EPU</intervention_name>
    <description>Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation</description>
    <arm_group_label>VISITAG SURPOINT Module with EPU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following inclusion criteria to be eligible for participation&#xD;
        in this study:&#xD;
&#xD;
          1. Symptomatic paroxysmal AF who had at least one AF episode electrocardiographically&#xD;
             documented within one (1) year prior to enrollment. Documentation may include&#xD;
             electrocardiogram (ECG); Transtelephonic monitoring (TTM), Holter monitor or telemetry&#xD;
             strip&#xD;
&#xD;
          2. Failed at least one antiarrhythmic drug (AAD) (Class I or III antiarrhythmic drugs) as&#xD;
             evidenced by recurrent symptomatic AF, or intolerable to the AAD&#xD;
&#xD;
          3. Age 18 years or older&#xD;
&#xD;
          4. Signed Patient Informed Consent Form (ICF)&#xD;
&#xD;
          5. Able and willing to comply with all pre-, post-, and follow-up testing and&#xD;
             requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following exclusion criteria are not eligible for enrollment.&#xD;
&#xD;
          1. Previous surgical or catheter ablation for atrial fibrillation&#xD;
&#xD;
          2. Previous cardiac surgery (including CABG) within the past 6 months (180 days)&#xD;
&#xD;
          3. Valvular cardiac surgical/percutaneous procedure (i.e., ventriculotomy, atriotomy, and&#xD;
             valve repair or replacement and presence of a prosthetic valve)&#xD;
&#xD;
          4. Any carotid stenting or endarterectomy&#xD;
&#xD;
          5. Documented LA thrombus on imaging&#xD;
&#xD;
          6. LA size &gt; 50 mm (parasternal long axis view)&#xD;
&#xD;
          7. LVEF &lt; 40%&#xD;
&#xD;
          8. Contraindication to anticoagulation (heparin or warfarin)&#xD;
&#xD;
          9. History of blood clotting or bleeding abnormalities&#xD;
&#xD;
         10. PCI/MI within the past 2 months (60 days)&#xD;
&#xD;
         11. Documented thromboembolic event (including TIA) within the past 12 months (365 days)&#xD;
&#xD;
         12. Rheumatic Heart Disease&#xD;
&#xD;
         13. Uncontrolled heart failure or NYHA function class III or IV&#xD;
&#xD;
         14. Severe mitral regurgitation (Regurgitant volume ≥ 60 mL/beat, Regurgitant fraction ≥&#xD;
             50%, and/or Effective regurgitant orifice area ≥ 0.40cm2)&#xD;
&#xD;
         15. Awaiting cardiac transplantation or other cardiac surgery within the next 12 months&#xD;
             (365 days)&#xD;
&#xD;
         16. Unstable angina&#xD;
&#xD;
         17. Acute illness or active systemic infection or sepsis&#xD;
&#xD;
         18. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac&#xD;
             cause.&#xD;
&#xD;
         19. Presence of implanted ICD/CRT-D.&#xD;
&#xD;
         20. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or&#xD;
             chronic obstructive pulmonary disease) or any other disease or malfunction of the&#xD;
             lungs or respiratory system that produces chronic symptoms.&#xD;
&#xD;
         21. Gastroesophageal Reflux Disease (GERD; active requiring significant intervention not&#xD;
             including OTC medication)&#xD;
&#xD;
         22. Significant congenital anomaly or medical problem that in the opinion of the&#xD;
             investigator would preclude enrollment in this study.&#xD;
&#xD;
         23. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal)&#xD;
&#xD;
         24. Concurrent enrollment in an investigational study evaluating another device, biologic,&#xD;
             or drug.&#xD;
&#xD;
         25. Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other&#xD;
             abnormality that precludes vascular access, or manipulation of the catheter.&#xD;
&#xD;
         26. Life expectancy less than 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grandview Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsville Hospital</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI St. Vincent</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Health</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Cardiac Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marian Regional Medical Center</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Providence</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JFK Medical Center</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Healthcare</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>92803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital/Cardiology Consultants</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory St. Joseph's</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Community</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Heart Institute</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington</name>
      <address>
        <city>Kensington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oschner LSU Health Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Medical Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erlanger Health System</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Health Heart and Vascular Hospital</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. David's Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Health</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Tacoma</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

